Pay in 4 interest-free payments of $7.36 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
Tirzepatide is a dual GIP/GLP-1 agonist with a different side effect profile
Focusing on a customer-centric approach, Hebei Shunxing Import and Export Co., Ltd has a pan-India presence and caters to a huge consumer base throughout the country
By merging modern technology with empathetic care, we help you focus on what really matters: your health and your progress
Emerging Therapy Retatrutide Retatrutide is a new emerging (LY-3437943) is a triple-agonist peptide targeting GIP, GLP-1, and glucagon receptors currently under trial conducted by Eli Lilly and Company Mechanism of Action GIP agonism enhances insulin release, suppresses appetite, inhibits fat accumulation GLP-1 agonism enhances insulin release, suppresses glucagon, slows gastric emptying Glucagon receptor agonism boosts energy expenditure, supports glycemic control Collectively, it addresses glucose homeostasis, appetite regulation, energy metabolism, and weight loss Competitive Edge over Existing Therapies Superior efficacy: Around 24% weight loss surpasses GLP-1-only treatments (e.g., semaglutide, tirzepatide)
Its always a joy coming in
